Stromal Cell-Derived Factor-1 Promotes Myeloma Cell Growth in Both Autocrine and Paracrine Manners

������������������������������������������������������������������������������������������������������������������������������ ������������������������������������������������������������������������������������������ Background: The question as to whether stromal cell-derived factor-1 (SDF-1) stimulated myeloma cell growth has been controversial. We explored the possibility that SDF-1 may function as an autocrine growth factor of myeloma cells. Methods: CD138+ primary bone marrow myeloma cells and myeloma cell lines (RPMI8226, U266, and ARH77) were used. Chemotaxis in response to SDF-1 of the cells was analyzed using TranswellsTM . Cell proliferation was measured by a colorimetric assay. SDF-1 mRNA expression was analyzed by RT-PCR (reverse-transcription-polymerase chain reaction). SDF-1 and interleukin-6 (IL-6) receptor expression as well as signaling molecule phosphorylation levels, were examined using Western blot analysis. Concentrations of SDF-1 in the cell culture supernatants were measured by ELISA assay. Results: SDF-1 alone had no discernible effect on the proliferation of CD138+ primary myeloma cells or myeloma cell lines. In contrast, SDF-1 significantly enhanced IL-6-induced proliferation of these cells. SDF-1 up-regulated the expression of IL-6 receptor and enhanced phosphorylation of AKT in an additive manner with IL-6. Co-culture of the myeloma cells with umbilical vein endothelial cells over-expressing the SDF-1 gene revealed that SDF-1 played an important role in not only the migration of the cells underneath the stromal cells but also the proliferation of the cells in contact with stromal cells. All the myeloma cell lines expressed SDF-1 mRNA, and SDF-1 was detected in the culture supernatants of the cells. The G protein-coupled receptor inhibitor, pertussis toxin, inhibited the proliferation of these cells in suspension cultures. Conclusion: SDF-1, most likely in concert with IL-6, enhanced the proliferation of myeloma cells in a both paracrine and autocrine manner. (Korean J Hematol 2008;43:127-137.)

[1]  T. Tsuruo,et al.  Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. , 2005, Cancer research.

[2]  D. Ribatti,et al.  Bone marrow endothelial cells in multiple myeloma secrete CXC‐chemokines that mediate interactions with plasma cells , 2005, British journal of haematology.

[3]  A. Zannettino,et al.  Elevated Serum Levels of Stromal-Derived Factor-1α Are Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients , 2005 .

[4]  A. Zannettino,et al.  Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. , 2005, Cancer research.

[5]  M. Amiot,et al.  1 VEGF INDUCES MCL-1 UPREGULATION AND PROTECTS MULTIPLE MYELOMA CELLS AGAINST APOPTOSIS , 2004 .

[6]  Andrés Hidalgo,et al.  Integrin α4β1 involvement in stromal cell-derived factor-1α-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion , 2004 .

[7]  Andrés Hidalgo,et al.  Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. , 2004, Experimental cell research.

[8]  S. Rudikoff,et al.  Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. , 2004, Blood.

[9]  W. Dalton,et al.  Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms , 2003, Leukemia.

[10]  R. Bende,et al.  The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma , 2003, Leukemia.

[11]  T. Horie,et al.  Requirement of soluble factors produced by bone marrow stromal cells on the growth of novel established human myeloma cell line. , 2003, International journal of oncology.

[12]  G. Nilsson,et al.  Expression and function of chemokine receptors in human multiple myeloma , 2003, Leukemia.

[13]  B. Dörken,et al.  In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. , 2002, Blood.

[14]  Mansoor M Ahmed,et al.  Didox (A Novel Ribonucleotide Reductase Inhibitor) Overcomes bcl-2 Mediated Radiation Resistance in Prostate Cancer Cell Line PC-3 , 2002, Cancer biology & therapy.

[15]  A. Gotoh,et al.  Enhancement of intracellular signaling associated with hematopoietic progenitor cell survival in response to SDF-1/CXCL12 in synergy with other cytokines. , 2002, Blood.

[16]  N. Munshi,et al.  The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. , 2002, Molecular cancer therapeutics.

[17]  J. Dürig,et al.  Differential expression of chemokine receptors in B cell malignancies , 2001, Leukemia.

[18]  A. Hidalgo,et al.  Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. , 2001, Blood.

[19]  Paul J. Williams,et al.  Cell–cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity , 2000 .

[20]  M. Le Bousse-Kerdilès,et al.  Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. , 2000, Blood.

[21]  T. Yoneda,et al.  Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. , 2000, Blood.

[22]  S. Rafii,et al.  E1(-)E4(+) adenoviral gene transfer vectors function as a "pro-life" signal to promote survival of primary human endothelial cells. , 1999, Blood.

[23]  R. Alon,et al.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. , 1999, Science.

[24]  T. Springer,et al.  The Chemokine SDF-1 Is a Chemoattractant for Human CD34+ Hematopoietic Progenitor Cells and Provides a New Mechanism to Explain the Mobilization of CD34+ Progenitors to Peripheral Blood , 1997, The Journal of experimental medicine.

[25]  S. Neben,et al.  Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. , 1994, Leukemia.

[26]  K. Anderson,et al.  Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. , 1993, Blood.

[27]  J. Greenberger,et al.  Quantitation of murine hematopoietic stem cells in vitro by limiting dilution analysis of cobblestone area formation on a clonal stromal cell line. , 1993, Experimental hematology.

[28]  F. caligaris-Cappio,et al.  Bone marrow microenvironment and the progression of multiple myeloma. , 1992, Leukemia & lymphoma.

[29]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.